PMID: 25738846Mar 5, 2015Paper

Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition

Journal of Drugs in Dermatology : JDD
Paul S Yamauchi, Jerry Bagel

Abstract

Advances in the understanding of the pathogenesis of psoriasis have led to the development of biologic agents that target T cells and cytokines that play a specific role in the underlying inflammation associated with psoriasis (eg, tumor necrosis factor-α inhibitors, interleukin [IL]-12/23 inhibitors). In this review, evidence for the central role of IL-17 in the pathophysiology of psoriasis is presented, along with available clinical trial data on the selective IL-17 inhibitors in development. Three biologic agents that target IL-17 are currently in clinical development: secukinumab, ixekizumab, and brodalumab. Clinical studies to date suggest a favorable safety profile and the potential for better efficacy over the previous generation of agents, with Psoriasis Area Severity Index 75 response rates of up to 80% or greater. Fully published results of phase III studies of these agents are eagerly awaited.

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Related Papers

Journal of Cutaneous Medicine and Surgery
Shivani Felicia Chandrakumar, Jensen Yeung
The Journal of Dermatological Treatment
Gabrielle BrownEthan Levin
Clinical, Cosmetic and Investigational Dermatology
Ann Sophie LønnbergLone Skov
© 2022 Meta ULC. All rights reserved